2011 - ISBTS 2011 Symposium


Oral Communications 7: Complications

9.155 - Pre-transplant predictors of ICU, hospital length of stay and long term patient survival after intestinal transplantation in a single center

Presenter: Hector, Solar Muñiz, Buenos Aires, Argentina
Authors: Hector Solar1, Patricia Guimaraens1, Adriana Crivelli1, Javier Romero1, Carolina Rumbo1, Gabriel Gondolesi1


155
Pre-transplant predictors of ICU, hospital length of stay and long term patient survival after intestinal transplantation in a single center

Hector Solar, Patricia Guimaraens, Adriana Crivelli, Javier Romero, Carolina Rumbo, Gabriel Gondolesi

Instituto de Trasplante Multiorganico Unidad de Rehabilitación, Nutrición y Transplante Intestinal, Hospital Universitario - Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Introduction: Outcome after intestinal transplantation (ITx) has improved over the last years as result of changes in surgical techniques; immunosuppression and close patient follow up among others. The aim of this study was to analyze the association of pre-ITx factors found at the time of the evaluation as predictors of post-ITx ICU length of stay (LOS), hospital LOS and patient survival in a single center.

Material and Methods: review of a prospectively  filled database including all patients who underwent a primary ITx or multiorgan Tx for intestinal failure from 3/2006 to 4/2011. Data collection consisted on 32 variables that were compared using chi-square and t- test, Cox regression model and Kaplan-Meier for actuarial survival using SPSS® v17.0.

Results: Data from 27/29 Tx patients were analyzed. Eigtheen were male, 18 children; 82% received isolated ITx, 18% multiorgan Tx (7% combined and 11% multivisceral). Median age was 6.17 years (0.8-15.6) for pediatrics and 41.8 years (18.6-58.9) for adults. Main intestinal failure etiologies were: volvulus 26%, Hirshprung’s disease 22%, gastrochisis 11%, ischemia 11%, others 30%. Forty one percent of the recipients had limited vascular accesses, being the main indication for ITx, followed by parenteral nutrition associated liver disease (22%) and central venous catheter infections (22%). The median time on waiting list: was 98 days (2-484). Of the 4 Multiorgan Tx, 2 died of primary graft non function on day 2 and 7 post transplant. One died with PTLD 112 days post transplant. The 3 years patient survival for the IITx group is 82%. In a univariate analysis was noted that younger recipient age (8.9±2.6 years), was associated with  longer hospital LOS (> 32 days) (p 0.02), while the lack of permeable vascular accesses at transplantation increased the ICU LOS  (> 10 days)(p 0.05). Hospitalization at time of ITx (p<0.002) and type of Tx (Multiorgan - p<0.001), were the only independent factors that manteined significance in the multivariate analyses.

Conclusion: Younger recipient age and lack of central venous accesses at the time of evaluation predict increased LOS at the time of ITx in our cohort of patients. In concordance with other single center reported experiences, to be hospitalized or to be  recipient of a multiorgan Tx impact the long term patient survival. 


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi